Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%
Low Eosinophil Patients Have 39% Reduction, Supporting Broad Label
Executive Summary
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
You may also be interested in...
Keeping Track: US FDA Approves Heron’s Zynrelef In Post-Op Pain; Amgen/AZ Submit Tezepelumab For Severe Asthma
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
AstraZeneca & Amgen Seek EU Fast-Track For Severe Asthma Drug
Tezepelumab was among four products that the European Medicines Agency most recently considered for review under its accelerated assessment mechanism.
Quick Listen: Scrip’s Five Must-Know Things
In this week's podcast edition of Scrip's Five Must-Know Things, hear about Sanofi’s rebates, Moderna’s business prospects, US views on coronavirus vaccine comparisons, Piot talk about virus variants, and new results for Amgen's asthma drug.